Compass Pathways Targets First-Half 2027 COMP360 Launch After Positive Phase III Data in Treatment-Resistant Depression

Compass Pathways查看公司主页 is preparing for a potential launch of COMP360查看药品详情 in the first half of 2027 after reporting statistically significant Phase III results for its synthetic psilocybin查看药品详情 formulation in treatment-resistant depression (搜索)搜索该疾病 (TRD), with the company aiming to be launch-ready by the end of 2026.

The Phase III program comprised two studies. COMP005 evaluated a single 25-milligram dose of COMP360查看药品详情 against placebo and was designed in part to establish a safety baseline. COMP006 evaluated 25-milligram, 10-milligram and 1-milligram doses, with two fixed doses administered three weeks apart. The 1-milligram dose was intended to provide some subjective effects rather than serve as an inert placebo, while the 10-milligram dose was intended to help assess dose response and blinding.

Both studies used a six-week primary endpoint and remained blinded through 26 weeks. According to the company, the trials showed statistically significant results on the primary endpoint, with a difference of just under four points in change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS).

Onset, Response Rates and Durability

Compass reported rapid onset, with patients who responded potentially showing improvement within 24 hours. Approximately one-quarter of patients had a clinically meaningful response following one administration, while roughly 40% responded after two doses given three weeks apart. The company also reported durability through 26 weeks, and data from COMP005 extending to 52 weeks indicated that a potential third dose had efficacy comparable with earlier doses.

Open-label data through 12 months, in which eligible patients received an additional dose at 26 weeks, showed that patients receiving that dose were able to sustain durability through the end of the year.

The most common adverse events were generally transient and occurred on the dosing day, including nausea, headache and fatigue. These events typically resolved within one or two days.

Dosing Burden Versus SPRAVATO

Compass expects its eventual label to specify two initial doses given at least three weeks apart, although physicians would decide whether a patient needs the second dose. The company anticipates patients could require two to four doses annually, with redosing at physician discretion.

Chief Commercial Officer Lori Englebert contrasted that potential schedule with Johnson & Johnson查看公司主页's SPRAVATO查看药品详情, which she said is administered twice weekly during the first month, weekly in the second month and then weekly or every other week for ongoing maintenance, potentially requiring roughly 25 to 50 administrations per year. Because of that treatment burden, many SPRAVATO patients do not continue beyond seven or eight months.

Englebert said approximately 4 million of the 13 million U.S. patients receiving drug treatment for major depressive disorder (搜索)搜索该疾病 have TRD, which the company defines as depression following failure of two antidepressants. She noted that 55 approved products are used annually for MDD but only one product is specifically indicated for TRD, SPRAVATO查看药品详情. Only about 2% of the TRD population is treated with SPRAVATO and another 2% receives electroconvulsive therapy or transcranial magnetic stimulation.

Compass plans to focus on newly identified TRD patients rather than targeting patients who are stable on SPRAVATO查看药品详情.

Sites, Coding and Rescheduling

Compass sees existing SPRAVATO查看药品详情 treatment infrastructure as a potential starting point for COMP360查看药品详情. Englebert said there are approximately 8,500 sites able to administer SPRAVATO and that those centers already have the rooms, staffing and monitoring capabilities needed for COMP360. Such sites are growing by about 500 per quarter and are not currently at capacity.

On reimbursement, Englebert said providers should not be disadvantaged relative to administering SPRAVATO查看药品详情 because they can initially use the same general evaluation and management billing codes. Compass plans to deploy a field reimbursement team at launch and encourage providers to attach Category III CPT codes, which could help support an eventual transition to Category I codes. The company also intends to seek a J-code for the drug and has applied for Category III Current Procedural Terminology codes specific to psychedelic treatment administration, intended to capture clinician work and practice expenses associated with observation, controlled-substance handling and other requirements.

Following a potential approval, federal rescheduling would be required because psilocybin查看药品详情 is currently a Schedule I substance. The Drug Enforcement Administration (搜索)搜索该词条 has up to 90 days by statute to reschedule a Schedule I drug following FDA approval, a process Englebert said could take from one to 90 days. States would then need to reschedule the product before it could be shipped and prescribed in those jurisdictions. Compass said it has worked with states and expects that states representing 93% of the U.S. population would reschedule within 30 days of federal action. The company expects a measured initial launch as it focuses on provider reimbursement, site readiness and patient education, followed by broader adoption as sites gain experience.

Regulatory Review Under a National Priority Voucher

Compass has received a National Priority Voucher, which establishes an FDA target of approval in 60 days or less after acceptance of an application, though the company emphasized that it is a target rather than a commitment. The voucher has also altered the company's interactions with the agency, with information requests, draft-label discussions, a Risk Evaluation and Mitigation Strategy framework, an eight-factor analysis and inspections already underway. Compass expects a standard 60-day acceptance period after completing its submission.

PTSD Program and Future Indications

Beyond TRD, Compass is advancing COMP360查看药品详情 in post-traumatic stress disorder (搜索)搜索该疾病. An open-label Phase II study in 22 patients was principally designed to assess safety, given concerns that the psychedelic experience could trigger adverse events in PTSD patients. The company did not observe those safety concerns and reported substantial efficacy, including remission in nearly 80% of participants at 12 weeks.

Compass has started a 300-patient late-stage PTSD study with three arms and two fixed doses. The study has an eight-week primary endpoint using the CAPS-5 assessment, followed by a blinded period through 12 weeks and open-label follow-up for one year. The company hopes the trial could serve as a single registrational study, although that determination would ultimately be subject to regulatory review. No enrollment or timing guidance has been provided.

Englebert estimated the PTSD population at about 13 million patients, approximately 60% of whom are women and 15% of whom are veterans, and said the last approved product in the indication was introduced 25 years ago. Compass has also identified substance-use disorders, particularly alcohol-use disorder (搜索)搜索该疾病, as a possible future area of interest, while stressing that it has made no commitments to pursue that indication.

COMP360查看药品详情 is a synthetic crystalline formulation of psilocybin查看药品详情. Compass Pathways查看公司主页 has conducted mid- and late-stage clinical trials evaluating the candidate and has also investigated its potential use in other difficult-to-treat psychiatric conditions, including post-traumatic stress disorder (搜索)搜索该疾病 and anorexia nervosa (搜索)搜索该疾病.